RHYTHM PHARMACEUTICALS, INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$190M
Cost of Revenue
$19M
R&D
$167M
SG&A
$195M
D&A
$500K
Operating Income
$-192M
EBITDA
$-192M
Interest Expense
$21M
Interest Income
—
Other Income/Expense
$17M
Pretax Income
$-196M
Tax Provision
$497K
Net Income
$-197M
Operating Margin
-101.2%
Net Margin
-103.6%
Effective Tax Rate
-0.3%
Deferred Tax Assets
$998K
DTA Valuation Allowance
$381M
NOL Carryforwards
$237M
ETR (Continuing Operations)
-0.3%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
-0.3%
Operating Lease Cost
—
Revenue YoY Variation
45.8%
Income YoY Variation
27.7%